Revvity has expanded its imaging portfolio with the introduction of three new imaging systems – the IVIS platform, the Quantum GX3 microCT, and the Vega ultrasound system.
Shimadzu has released the AIMsight infrared microscope. AIMsight builds on the high sensitivity of Shimadzu’s well-known AIM-9000 to offer an improved operational experience through greater automation. AIMsight is intended for industrial applications, such as drug manufacturing.
The COMBO-ONE Viscometer/DRI detector from TESTA Analytical sets a new standard for demanding GPC/SEC applications, such as those focused on investigating the structure and branching of polymers.
INTEGRA Biosciences has launched MIRO CANVAS, a compact digital microfluidics platform for fully automated next generation sequencing (NGS) sample preparation. The revolutionary system significantly simplifies NGS workflows for more walk-away time and higher lab productivity.
The life science group Sartorius and UK-based start-up SPARTA Biodiscovery have agreed to partner on SPARTA’s analysis platform, which helps speed up the development, manufacture, and quality control of nanoparticles for bio-pharmaceutical drugs.
Revvity and Element Biosciences, the developer of the AVITI System [1], a genomic sequencing platform, will collaborate to introduce workflow solutions that are more efficient for genomic analysis of samples.
Rockville, Maryland, US-based Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, has acquired VaxTRIALS. Headquartered in Panama City, Panama, VaxTRIALS’ 160+ staff members manage and monitor vaccine clinical trial activities throughout Latin America.
Biosynth, a supplier of critical materials to the life science industry, has acquired Pepceuticals, a UK producer of synthetic peptides with multi-kilogramme GMP facilities and fill-finish capabilities designed to support customers from clinical trials to commercial supply.
SpliceBio, a Barcelona, Spain-based genetic medicines company harnessing protein splicing to develop the next generation of gene therapies, has signed an exclusive collaboration and licensing agreement with Philadelphia, Pennsylvania-based Spark Therapeutics to utilize SpliceBio’s proprietary protein splicing platform to develop a gene therapy for an undisclosed inherited retinal disease.
Gilead Sciences has entered into a 12-year partnership with Assembly Biosciences, a biotechnology company developing antiviral therapeutics targeting serious viral diseases. The partnership, announced 17 October, aims to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D […]
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
